From first partnering conversation to post-deal alliance management — CartaOS gives clinical-stage biotechs the BD intelligence layer they can't afford to hire, and can't afford to operate without.
Clinical-stage biotechs are built by scientists. But the decisions that determine their fate — licensing deals, M&A, post-deal alliances — require a completely different kind of intelligence. One that comes only from sitting on the buy-side of hundreds of deals. Most small biotechs have never had that vantage point.
They enter data rooms without knowing what to share or redact. They sign deals with milestone structures that undervalue their asset. And once the deal is signed, they have no system to manage the partnership — the phase where most value is made or destroyed.
A second gap goes untapped: Korean, Chinese, and Taiwanese biotechs sitting on genuinely innovative clinical assets that Western pharma systematically undervalues — not because the science is weak, but because the translation doesn't exist.
CartaOS covers the full lifecycle — from pre-deal asset positioning through active alliance management and competitive threat monitoring. Each phase feeds the next. Each creates a reason to stay.
The deal signing is the beginning, not the end. Most biotechs celebrate the close and then improvise what comes next. Joint steering committees become political. Milestones drift. Integration fails not because of science — but because nobody mapped who needs to be in the room, and when.
CartaOS's alliance management layer is the reason clients log in every single week — not just during deal moments. It's the stickiest part of the platform, and the most underserved by every existing tool in the market.
The intelligence layer runs continuously — monitoring the external environment so you know what's changing before it affects your deals, partnerships, or supply chain.
Predict when a partner is quietly deprioritizing your collaboration before they tell you. Combines publication signals, pipeline announcements, hiring patterns, and organizational restructuring.
For deals with Asian manufacturing, CRO networks, or API suppliers — monitor the macro environment that could disrupt your collaboration long before your legal team notices.
Track the external landscape your deal was built on. If something changes the strategic rationale of your partnership, you need to know immediately — not at the next JSC meeting.
East Asian biotechs are systematically undervalued by Western pharma — not because the science is weak, but because the translation, the relationship infrastructure, and the risk framing don't exist on either side of the table.
The Biotheus deal — $11B with BMS — was an asset our founder evaluated from the BioNTech buy-side. The ability to read East Asian science through a Western BD lens, before the rest of the market does, is proven. CartaOS systematizes it.
Every feature reflects lived experience from inside one of Europe's most active oncology deal pipelines. This is not a platform built by engineers guessing at what BD teams need.
3.5 years leading due diligence on clinical-stage oncology assets worth over $950M. Knows exactly what triggers a go/no-go in a BD committee — and what kills deals that should have lived.
Direct evaluation of Chinese and Korean biotech assets from the European pharma buy-side. The Biotheus pipeline — part of the $11B BMS deal — was in scope. This is not a theory.
BSc Biomedicine, Karolinska Institute. MSc Business, Stockholm School of Economics. Research at Harvard Medical School, KAUST, and Hasso Plattner Institute.
Germany, Sweden, US, China, Saudi Arabia. Co-founded Iris — scaled to 300,000 users in China's WeChat ecosystem. VC experience at Earlybird. The range is operational, not decorative.
Monthly retainers that grow with the deal lifecycle. Clients stay 3–5 years — the full window from Series B to liquidity event. The alliance management layer alone gives teams a reason to log in every week.
Early conversations open with investors who understand what it means to embed buy-side M&A judgment into every critical deal and alliance a clinical-stage biotech makes — East and West.
Request an Investor Briefing